Gabapentin Should Be Preferred Over Ropinirole for Restless Legs Syndrome
Based on the most recent 2025 American Academy of Sleep Medicine guidelines, gabapentin receives a strong recommendation for RLS treatment, while ropinirole is explicitly recommended against for standard use due to the significant long-term risk of augmentation. 1
Current Treatment Hierarchy
The 2025 AASM guidelines represent a fundamental paradigm shift in RLS management:
First-Line Agents (Strong Recommendations)
- Gabapentin (strong recommendation, moderate certainty) 1
- Gabapentin enacarbil (strong recommendation, moderate certainty) 1
- Pregabalin (strong recommendation, moderate certainty) 1
Ropinirole Status
The AASM explicitly suggests AGAINST the standard use of ropinirole (conditional recommendation, moderate certainty of evidence) 1. The guideline includes a critical remark: ropinirole may only be considered in patients who place higher value on short-term symptom reduction and lower value on long-term adverse effects, particularly augmentation 1.
Why This Represents a Major Change
The Augmentation Problem
Augmentation is a treatment-related worsening of RLS where symptoms:
- Begin earlier in the day
- Spread to previously unaffected body parts (often upper limbs)
- Increase in severity
- Require progressively higher doses that paradoxically worsen symptoms 2, 3
This complication has fundamentally altered the risk-benefit calculation for dopamine agonists like ropinirole, leading to their demotion from first-line status 4, 3.
Evidence Quality Comparison
While both medications demonstrate short-term efficacy, the evidence profiles differ substantially:
Ropinirole:
- FDA-approved with demonstrated 12-week efficacy in three trials 5
- Mean IRLS score improvements of 2.5-3.7 points versus placebo 5
- However, long-term use carries moderate certainty evidence of augmentation risk 1
Gabapentin:
- Strong recommendation with moderate certainty evidence 1
- Improves both objective sleep architecture and subjective sleep quality 6
- Does not carry augmentation risk 6, 7
Clinical Decision Algorithm
Step 1: Check Iron Status
Before initiating any pharmacotherapy, assess ferritin and transferrin saturation. If ferritin <75-100 ng/mL, iron supplementation (oral or IV) should be first-line 1, 3.
Step 2: If Iron Adequate, Choose Gabapentinoid
Start gabapentin 300 mg 1-2 hours before symptom onset, titrating up to 800-1200 mg as needed based on response 7. Alternatively, use gabapentin enacarbil or pregabalin per guideline recommendations 1.
Step 3: Reserve Ropinirole for Specific Scenarios Only
Ropinirole should only be considered if:
- Patient has failed gabapentinoids
- Patient explicitly prioritizes immediate symptom relief over long-term safety
- Treatment duration will be short-term only
- Patient is counseled extensively about augmentation risk 1
If ropinirole is used, start at 0.25 mg once daily 1-3 hours before bedtime, with maximum dose 4 mg 5.
Comparative Efficacy Evidence
A 2017 network meta-analysis found no significant differences between gabapentin enacarbil, pregabalin, and rotigotine in terms of IRLS score changes, though gabapentin enacarbil showed numerically superior CGI-I response rates 8. Importantly, this analysis predates the current understanding of augmentation's clinical significance.
A direct comparison study showed gabapentin improved sleep efficiency and latency significantly, while ropinirole did not 6. Gabapentin also improved slow-wave sleep and subjective sleep quality, whereas ropinirole showed opposite effects on sleep architecture 6. While ropinirole reduced periodic leg movements more dramatically (-73% vs -35%), this did not translate to better functional outcomes 6.
Critical Pitfalls to Avoid
Do not start ropinirole as first-line therapy - This contradicts current 2025 guidelines and exposes patients to unnecessary augmentation risk 1, 3
Do not ignore iron status - Even with normal hemoglobin, ferritin <75-100 ng/mL warrants iron supplementation as primary or adjunctive therapy 1, 3
Do not continue ropinirole long-term without reassessment - If a patient is already on ropinirole, consider transitioning to gabapentinoids, especially if symptoms are worsening or occurring earlier in the day 2, 3
Do not use ropinirole in patients with end-stage renal disease - In ESRD patients, gabapentin specifically receives a conditional recommendation, while dopamine agonists do not 1
Special Population Considerations
In patients with end-stage renal disease, gabapentin is specifically recommended (conditional recommendation, very low certainty), while ropinirole receives no specific recommendation for this population 1, 9. Dose adjustment is required for renal impairment with gabapentin.
The 2025 guidelines mark a definitive shift toward augmentation-aware, iron-conscious treatment that prioritizes long-term sustainability over short-term efficacy alone 4. This represents the most significant change in RLS management in over a decade.